The Berkeley biotech is backing a Nature-published approach that recreates the embryonic environment where blood stem cells first form, rather than reprogramming aged cells chemically or genetically. Its lead programme targets bone marrow transplant in blood cancers and has received FDA Orphan Drug Designation. HexemBio has publicly launched with a $10.4 million seed round led […]
This story continues at The Next Web